Confronting Illusions of Quality in Indian Generics Manufacturing
This article was originally published in The Gold Sheet
Executive Summary
A sharp increase in data integrity findings has raised questions about the quality of pharmaceutical manufacturing in India. What’s happening and why, who’s responsible, and how can drug makers and the regulatory agencies that watch over them put a stop to it?
You may also be interested in...
US FDA: Sun’s Mohali Plant Dropped Ball On Worker’s Data Integrity Allegations
Was backdating of GMP records part of an effort to move suspect product? FDA investigators found Sun was leaving lots of stones unturned in its effort to find out.
Greater US FDA And Manufacturer Transparency Recommended As Key to Supply Chain Resilience
Manufacturers could risk losing FDA product approvals if they fail to publicize sourcing and quality information, under new proposals. National Academies expert panel says supply chain transparency – not a pandemic-induced rush to onshoring requirements – provides the framework to mitigate against and respond to drug shortages.
US FDA Looks To Resume Unannounced Inspections In India And China
After lapsing due to COVID-19, an unannounced foreign inspection pilot program is on track to resume in 2022, “despite challenges and constraints of travel.”